University of Minnesota
https://twin-cities.umn.edu/
612-625-5000
Milestone
6.1.a

Full value assessment (FVIVA)

In progress
High priority

Develop and disseminate a full value of vaccine assessment (FVVA; also referred to as the full value of influenza vaccine assessment [FVIVA]) for improved seasonal and broadly protective, universal influenza vaccines that addresses different vaccine use cases and includes an assessment for low- and middle-income countries (LMICs).

Progress Highlights

White 2024 summarized WHO’s FVVA framework for documenting evidence for the value of vaccines, including the broader socioeconomic consequences of vaccines, and prioritizing vaccine candidates for investment and deployment in LMICs.

See research
 

Bresee 2023: WHO is developing the FVIVA, which is expected to be completed by late 2024 and includes three workstreams: (1) vaccine products and supply; (2) market potential for next-generation influenza vaccines; and (3) expected health and economic impact of global distribution and uptake of next-generation seasonal influenza vaccines.

See research


Hutubessy 2023 published a conceptual framework for the FVVA, designed to: (1) guide the assessment and communication regarding new vaccines, (2) facilitate alignment across key stakeholders, and (3) enhance decision-making on investment in vaccine development, policymaking, and deployment particularly for vaccines intended for use in LMICs.

See research

Soble 2025 identified, mapped, and prioritized 9 use cases for seasonal influenza vaccines, corresponding to the most common modes of influenza vaccine delivery in WHO-recommended target populations. The data can be used to assess barriers that limit the wider use of current influenza vaccines and evaluate the potential public health and economic impact of improved influenza vaccines.

See research